x
ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2020 > CANCELLED: 19th ESO-ESMO Masterclass in Clinical Oncology
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

CANCELLED: 19th ESO-ESMO Masterclass in Clinical Oncology

Not eligible for ESCO credits

21.03.2020  -  26.03.2020

Seva (Barcelona area), Spain

MASTERCLASS

Medical / clinical oncology

Important information

On behalf of ESO and ESMO we would like to inform you that due to the ongoing Coronavirus (COVID-19) crisis we have made the difficult decision to cancel the 19th ESO-ESMO Masterclass in Clinical Oncology programmed for 21st to 26th March in Seva (Barcelona area), Spain.

We deeply regret having to take this decision but we feel that in the current climate we all need to do our part in trying to limit the diffusion of the virus as much as possible and this was the only decision possible considering your role in society as medical staff.

We have discussed the possibility of postponing the event to later this year, but due to other already planned activities we have decided that postponing is not a viable solution.

We apologize for any inconvenience caused but we think you’ll all agree that this solution was unavoidable.

Description

Chairs: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Advisors: F. Lordick, DE - R. Popescu, CH


AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam.
The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, gastro-intestinal, lung, genito-urinary, gynaecological, head and neck cancers.
Spotlight sessions will facilitate compact update on mentorship, cancer of unknown primary, molecular tumour board (including liquid biopsy), cultural diversity, basic public speaking, immuno-oncology, melanoma, nutrition, neuroendocrine tumours, burn-out syndrome, early integration in oncology and palliative care, fertility presentation and pregnancy in cancer patients, brain tumours, mind body medicine.


TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairmen and the faculty. Informal discussion will be facilitated during the lunches and the aperitifs with the experts.
All participants will reside at the course venue and participation is compulsory throughout the course.
The Masterclass will be entirely in English and fluency in English is necessary for admission.
Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the communication skills sessions will be attended jointly.

THE MASTERCLASS IS
• A 5-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.


The Masterclass in
Clinical Oncology is an
ESO-ESMO joint event

     

The Masterclass is held
in collaboration with the
Flims Alumni Club

   

The 2020 Masterclass is part of
the Masterclass-Online Study
Program in Advanced Oncology
of the University of Ulm

     

 

In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”

Download PDF document

Faculty

INVITED FACULTY
A. Aapro, Clinique de Genolier, CH
A. Arber
, University of Surrey, Faculty of Health and Medical Sciences, Guildford, UK
J. Arends, Freiburg University Hospital, Freiburg, DE
S. Banerjee, The Royal Marsden NHS Trust Foundation, London, UK
G. Curigliano
, European Institute of Oncology, Milan, IT
M. De Santis, Charité University Hospital, Berlin, DE
A. Dietz, University Hospital Leipzig, Leipzig, DE
A. Eggermont, Princess Máxima Center for Pediatric Oncology, Utrech, NL
A. Eniu, Cancer Institute "Ion Chiricuta", Cluj-Napoca, RO
K. Fizazi, Institut Gustave Roussy, Villejuif (Paris), FR
T. Gagliardi, Royal Marsden Hospital, London, UK
W. Gatzemeier, Humanitas Cancer Center, Rozzano, IT
D. Hart, Cameron Communications, London, UK
S. Hillinger, University Hospital, Zurich, CH
A. Hoy, Consultant in Palliative Medicine, Epson, UK
S. Joosse, University Medical Center Hamburg-Eppendorf, Hamburg, DE
N. Koppotsch, Charité University Hospital, Berlin, DE
A. Letsch, Universitätsklinikum Schleswig-Holstein, Kiel, DE
F. Lordick, University Hospital Leipzig, University Cancer Center, Leipzig, DE
F. Mc Donald, The Royal Marsden NHS Foundation Trust, London, UK
R. Orecchia, European Institute of Oncology, Milan, IT
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
N. Pavlidis, University Hospital of Ioannina, Ioannina, GR
F.A. Peccatori, European Institute of Oncology, Milan, IT
M. Pera, Universitat Autónoma de Barcelona, Barcelona, ES
R. Popescu, Hirslanden Klinik Aarau, Tumor Center, Aarau, CH
G. Pruneri, University of Milan – European Institute of Oncology, Milan, IT
M. Schumacher, Hirslanden Klinik Aarau, Aarau, CH
C. Sessa, Oncology Institute of Southern Switzerland, Bellinzona, CH
L. Sharp, Regional Cancer Centre, Stockholm, SE
R.A. Stahel, University Hospital, Zurich, CH
C. Toumpanakis, Royal Free Hospital, London, UK
E. Van Cutsem, University Hospital Leuven, Leuven, BE
R. Verity, King's College London, London, UK
J.B. Vermorken, Antwerp University Hospital, Edegem, BE
M. Weller, University Hospital Zurich, Zurich, CH
C. Witt, University Hospital Zurich and University of Zurich, Zurich, CH
I. Zapardiel, La Paz University Hospital, Madrid, ES

General information

ORGANISING SECRETARIAT                       
Alice Ciocchini                            
Ph: +39 02 85464529                           
Email: aciocchini@eso.net                         
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Fax: +39 02 85464545

Applications
Corinne Hall
Ph: +39 02 85464522
Email: chall@eso.net

ACCREDITATION
Application for CME recognition will be submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.

SOCIAL MEDIA
Follow updates, send questions and join in the discussions using #20MCO on Twitter and Facebook.

IMPORTANT DEADLINES

Application deadline: 01 December 2019  
Save event date: 21 March 2020  
Early registration by: insert the date  
Late registration by: insert the date  
Onsite registration from: insert the date  

Application

IDEAL MASTERCLASS CANDIDATE
• Age between 30 and 40 years
• At least 2-3 years’ experience in medical oncology or clinical oncology
• Involvement in scientific activities
• Fluency in English

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and accommodation
THE APPLICATION DEADLINE HAS PASSED (1 DECEMBER 2019)

Programme

21 March

    Participants' arrival, airport transfers, registration
 13:00   Lunch      
 14:00   Focus on ESO, ESMO and EONS
N. Pavlidis, GR - R. Stahel, CH - R. Verity, UK
    PARALLEL SESSIONS
14:30   Communication Skills Workshop - 2 Groups
A. Arber, UK - A. Hoy, UK       
14:30   Warm up + Case presentations by participants - 2 Groups
R. Popescu, CH - R.A. Stahel, CH
16:30
  Coffee break
17:00   Communication Skills Workshop - 2 Groups 
A. Arber, UK - A. Hoy, UK
17:00
  Warm up + Case presentations by participants - 2 Groups
F. Lordick, DE - N. Pavlidis, GR
20:00   Dinner    

 

 22 March

 8:15   Clinical session Lung cancer   
Chair: R.A. Stahel, CH
    Systemic therapy for NSCLC without oncogenic driver mutations
R.A. Stahel, CH
Systemic therapy for NSCLC with oncogenic driver mutation
R.A. Stahel, CH
Radiotherapy in the treatment of NSCLC
F. Mc Donald, UK
Multimodality treatment of SCLC
F. Mc Donald, UK
General discussion   
11:00   Coffee break  
 11:30   Tumour board Lung cancer    
R.A. Stahel, CH - F. Mc Donald, UK - S. Hillinger, CH
 12:30   Spotlight session Burnout syndrome
S. Banerjee, UK  
 13:00   Lunch with the expert
 14:00   Molecular Tumour Board (including Liquid Biopsy)
S. Joosse, DE
 14:40   Spotlight session Mentorship   
R.A. Stahel, CH
 15:10   Spotlight session Cultural Diversity
L. Sharp, SE
15:40   Spotlight session Basic public speaking
D. Hart, UK
 16:25   Case presentations by participants (4 groups)
F. Lordick, DE - N. Pavlidis, GR - R. Popescu, CH - R.A. Stahel, CH
 19:30   Dinner
21:00   Games night

 

 23 March

8:15
  Clinical session Gastro-intestinal tumours   
Chair: E. van Cutsem, BE  
    Systemic treatment in early and advanced gastric cancer   
F. Lordick, DE     
Principles of oncological surgery - the example of esophago-gastric surgery   
M. Pera, ES
Pancreatic cancer   
R. Popescu, CH
Systemic treatment in adjuvant setting in colon cancer   

E. van Cutsem, BE     
10:15   Coffee break         
    Systemic treatment in advanced colon cancer
E. van Cutsem, BE
The role of surgery in stage IV gastrointestinal cancer 
M. Pera, ES
    General discussion
12:00   Tumour board Gastro-intestinal tumours    
F. Lordick, DE - R. Popescu, CH - E. van Cutsem, BE - M. Pera, ES
13:00   Lunch with the expert
14:00   Spotlight session Case presentations (3 cases) on Immunoncology
G. Curigliano, IT
14:45   Spotlight session Immunoncology
G. Curigliano, IT
 15:40   Spotlight session Melanoma
A. Eggermont, NL
16:30   Coffee break
17:00   Spotlight session Nutrition
J. Arends, DE
17:30   Spotlight session Cancer in Elderly patients
M. Aapro, CH
 19:30  
Dinner

 

 24 March

8:15   Clinical session Breast cancer (early and advanced)   
Chairs: O. Pagani, CH - A. Eniu, RO  
    Radiology
T. Gagliardi, UK
Surgery
W. Gatzemeier, IT
Pathology
G. Pruneri, IT
Radiation therapy
R. Orecchia, IT
Systemic treatment
O. Pagani, CH
10:20   Coffee break        
    (Advanced breast cancer pathway)
Systemic treatment
G. Curigliano, IT
Palliative care
R. Verity, UK
Oligometastatic disease
A. Eniu, RO 
12:00   Tumour board Breast cancer    
G. Curigliano, IT - O. Pagani, CH - W. Gatzemeier, IT - A. Eniu, RO - G. Pruneri, IT - R. Orecchia, IT - T. Gagliardi, UK - R. Verity, UK
13:00   Lunch with the expert
14:00   Spotlight session Fertility preservation and pregnancy in cancer patients
F.A. Peccatori, IT
14:45   Women in oncology and early integration in oncology and palliative care
A. Letsch, DE
15:25   Spotlight session Case presentation by a doctor and a nurse
A. Letsch, DE - N. Koppotsch, DE
16:20   Spotlight session Neuroendocrine tumours
C. Toumpanakis, UK
18:30   Networking Aperitif
 19:30   Dinner     

 

 25 March

8:15   Clinical session Genito-urinary cancers   
Chair: K. Fizazi, FR
    Localized prostate cancer   
M. Schumacher, CH
Treatment of metastatic castration sensitive prostate cancer   
K. Fizazi, FR      
Castration-resistant prostate cancer   
K. Fizazi, FR      
Metastatic renal cancer: evidence-based treatment   
M. De Santis, DE  
Treatment of bladder cancer
M. De Santis, DE
General discussion                  
10:45   Coffee break
11:15   Tumour board Genito-urinary cancers    
K. Fizazi, FR - R. Orecchia, IT - M. Schumacher, CH -M. De Santis, DE
12:15   Cancer of Unknown Primary
N. Pavlidis, GR
13:00   Lunch with the expert
 14:00   Clinical session Head and neck cancer   
Chair: Jan B. Vermorken, NL
    Prognostic factors and surgical approach  
A. Dietz, DE     
Radiotherapy   
R. Orecchia, IT
Systemic therapy and radio- chemo-therapy   
J.B. Vermorken, NL
General discussion

 16:00   Tumour board Head & Neck cancer
A. Dietz, DE - R. Orecchia, IT - J.B. Vermorken, NL
16:30   Spotlight session Brain tumours
M. Weller, CH
18:30   Networking Aperitif
19:30   Dinner

 

 26 March

 8:15   Clinical session Gynaecological cancers   
Chair:
J.B. Vermorken, BE
    Screening of endometrial and cervical cancer
C. Sessa, CH
Role of surgery in gynecological cancers
I. Zapardiel, ES
Systemic management of ovarian cancer
J.B. Vermorken, BE
Management of endometrial and cervical cancer
C. Sessa, CH
10:30   Coffee break
 11:00   Tumour board Gynaecological cancers (2 cases)
J.B. Vermorken, DE - C. Sessa, CH - I. Zapardiel, ES
11:30   Learning Assessment Test
 12:30   Spotlight session Body mind medicine
C. Witt, CH
 13:00   Closing remarks and Awards (13:00 - 13:15)